Del Prato S, Kahn SE, Pavo I et al (2021) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
So you have nothing to lose by trying the one that feels right for you
Kidney function deserves attention with both medications, particularly in patients with pre-existing renal concerns
An analytical study based on post-marketing approval pharmacovigilance data, Frontiers in Endocrinology (2022) Effects of semaglutide on chronic kidney disease in patients with Type 2 diabetes, The New England Journal of Medicine (2024) Medicines to manage kidney disease, American Kidney Fund Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
What they documented was a series of failures that strike at the most fundamental requirements for producing sterile injectable medications
Understanding Compounded Semaglutide Side Effects. Medivera RX , Accessed September 2024
